What are TACE and radioembolisation?
TACE (transarterial chemoembolisation) and radioembolisation, also called SIRT (selective internal radiation therapy) or TARE (transarterial radioembolisation), are treatments for tumours in the liver. Both deliver treatment directly into the blood vessels that feed the tumour, through a thin tube passed from an artery in the groin or wrist.
In TACE, a chemotherapy drug is injected into the tumour’s artery, followed by tiny particles that block the blood supply. The tumour is starved of oxygen and exposed to a high dose of chemotherapy at the same time.
In radioembolisation, millions of microscopic beads (microspheres) containing the radioactive element yttrium-90 are injected into the artery. They lodge in the small vessels of the tumour and give off radiation from inside it over the following two weeks.
Why the liver suits this approach
The liver has an unusual double blood supply. Healthy liver tissue gets most of its blood from the portal vein, while liver tumours get most of theirs from the hepatic artery. Treatment given into the hepatic artery therefore reaches tumours far more than it reaches the normal liver.
TACE and SIRT compared
| Feature | TACE | Radioembolisation (SIRT) |
|---|---|---|
| Active agent | Chemotherapy (often doxorubicin or cisplatin) | Yttrium-90 microspheres |
| Blocking the artery | A main part of the effect | Minimal; the beads are tiny |
| Planning procedure | Usually not needed | A preliminary mapping procedure is needed |
| Number of sessions | Often repeated every few months | Often a single treatment per liver lobe |
| Typical stay | Usually one night | Often a day case |
| Post-procedure symptoms | Post-embolisation syndrome is common | Usually milder |
Who performs it
These treatments are carried out by interventional radiologists, doctors who specialise in using imaging to guide small instruments through blood vessels. Decisions about whether TACE or SIRT is right for you are usually made by a liver multidisciplinary team, including liver specialists, surgeons, oncologists and radiologists.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of treatment | Liver-directed, catheter-based treatment |
| Main uses | Hepatocellular carcinoma; liver metastases from bowel, neuroendocrine and other cancers |
| How it is given | Through a catheter inserted into an artery in the groin or wrist |
| Anaesthetic | Local anaesthetic with sedation |
| Procedure time | About 1-2 hours |
| Hospital stay | Day case or one night |
| Repeats | TACE is often repeated; SIRT is usually one or two sessions |
| Main side effects | Pain, nausea, fever and tiredness for a few days; rarely liver damage |
2. How it works
TACE
| Step | Effect |
|---|---|
| 1. Catheter in the tumour artery | Treatment is aimed at the tumour |
| 2. Chemotherapy delivery | The drug is mixed with an oily contrast called lipiodol or loaded onto drug-eluting beads |
| 3. Embolisation | Particles block the artery, cutting off blood and oxygen |
| 4. Drug retention | The drug stays in the tumour longer because blood flow is slowed |
| 5. Tumour death | The combination of oxygen starvation and chemotherapy kills cancer cells |
Types of TACE
| Type | Description |
|---|---|
| Conventional TACE (cTACE) | Chemotherapy mixed with lipiodol, followed by blocking particles |
| Drug-eluting bead TACE (DEB-TACE) | Small beads soaked in chemotherapy release the drug slowly once lodged in the tumour |
| Bland embolisation (TAE) | Particles only, without chemotherapy |
Studies comparing these approaches have generally shown similar effectiveness, and the choice usually depends on the experience of the centre.
Radioembolisation
| Step | Effect |
|---|---|
| 1. Mapping | A planning angiogram checks the blood vessels and blocks any that lead to the gut |
| 2. Lung shunt test | A tracer scan measures how much would travel to the lungs |
| 3. Microsphere injection | Y-90 beads are injected into the artery feeding the tumour |
| 4. Radiation | Beta radiation travels only a few millimetres, mainly affecting the tumour |
| 5. Decay | Most radiation is delivered within about two weeks |
This is a form of internal radiotherapy, related to brachytherapy, in which the radiation source is placed inside the body close to the cancer.
3. Who it is for
Conditions treated
| Condition | Role |
|---|---|
| Hepatocellular carcinoma | TACE is standard for intermediate-stage disease; SIRT is used for selected early and intermediate tumours and some with vessel invasion |
| Fibrolamellar carcinoma | Sometimes used for liver disease that cannot be removed |
| Intrahepatic cholangiocarcinoma | Used for unresectable disease, often with chemotherapy |
| Colorectal adenocarcinoma | SIRT or chemoembolisation for liver-dominant metastases after other treatments |
| Gastrointestinal neuroendocrine tumours | Liver metastases, to control tumours and hormone symptoms |
| Pancreatic neuroendocrine tumours | Liver metastases |
| Uveal melanoma | Liver metastases, which are common in this cancer |
Who may be suitable
| Factor | Typical requirement |
|---|---|
| Disease in the liver | Tumours mainly or only in the liver |
| Liver function | Reasonably preserved, often Child-Pugh A or early B |
| General fitness | Able to manage day-to-day activities |
| Blood flow | Suitable artery anatomy; for SIRT, limited flow to the lungs |
| Bile ducts | No major blockage of the bile ducts |
Who may not be suitable
| Situation | Reason |
|---|---|
| Severe liver failure or jaundice | High risk of further liver damage |
| Widespread cancer outside the liver | Systemic treatment is usually preferred |
| Main portal vein blocked by tumour | TACE may cause liver damage; SIRT may still be possible |
| High lung shunt | Too much radiation would reach the lungs |
4. Before treatment
| Step | Why it is done |
|---|---|
| CT or MRI | Shows the tumours and blood vessels |
| Blood tests | Liver function, kidney function, clotting and blood counts |
| Liver function scoring | Helps predict safety |
| SIRT work-up angiogram | Maps vessels and measures lung shunt about 1-3 weeks before treatment |
| Medicines review | Blood thinners may need adjusting |
| Fasting | Usually for several hours before the procedure |
5. What to expect: step by step
| Step | What happens |
|---|---|
| 1. Preparation | A cannula is placed; you may receive anti-sickness medicine and antibiotics |
| 2. Sedation and local anaesthetic | The groin or wrist is numbed; you stay awake but relaxed |
| 3. Catheter insertion | A thin tube is passed into the artery |
| 4. Navigation | Using X-ray imaging and contrast, the tube is steered into the liver artery |
| 5. Treatment | Chemotherapy and particles (TACE) or microspheres (SIRT) are injected |
| 6. Removal | The catheter is removed and pressure or a closure device stops bleeding |
| 7. Bed rest | Several hours lying flat if the groin was used |
| 8. Observation | Pain, nausea and vital signs are monitored |
| 9. Home | The same day or next day |
After SIRT
A scan is usually done shortly after treatment to show exactly where the microspheres have gone. Radiation precautions are minimal, but close contact with pregnant women and young children may be limited for a short period, as advised.
6. Side effects and risks
| Side effect or risk | TACE | SIRT |
|---|---|---|
| Post-embolisation syndrome (pain, fever, nausea) | Common, lasting several days | Less common, milder |
| Tiredness | Common | Common, may last weeks |
| Groin bruising | Common | Common |
| Liver function worsening | Possible, especially with cirrhosis | Possible; radiation-induced liver disease is rare |
| Liver abscess | Rare | Rare |
| Gallbladder inflammation | Rare | Rare |
| Stomach or duodenal ulcer | Rare | Rare, if beads reach the gut |
| Radiation pneumonitis | Not applicable | Very rare, if too much reaches the lungs |
| Hair loss | Uncommon | Not expected |
7. Results and outlook
| Study | Main finding |
|---|---|
| Llovet and colleagues, unresectable HCC (112 people) | Chemoembolisation improved two-year survival to 63% compared with 27% with supportive care alone (Llovet et al., 2002) |
| Lo and colleagues, unresectable HCC in Asian patients (80 people) | Lipiodol chemoembolisation with cisplatin raised two-year survival to 31% versus 11% with symptomatic care (Lo et al., 2002) |
| SARAH, locally advanced HCC (459 people) | SIRT did not lengthen survival compared with sorafenib (8.0 versus 9.9 months), but some side effects such as diarrhoea and fatigue were less frequent (Vilgrain et al., 2017) |
The two 2002 trials established TACE as a standard treatment for intermediate-stage liver cancer. SIRT has not beaten tablet treatment in advanced disease, but it is often used for earlier tumours, for people who cannot have TACE, and as a way to shrink tumours before surgery or transplant.
Bridging and downstaging
People waiting for a liver transplant may have TACE or SIRT to stop the cancer growing while they wait. This is called bridging. In others whose tumours are slightly too large or too many for transplant, these treatments may shrink the cancer to within the accepted limits, which is called downstaging. Success depends on careful selection and close follow-up scans.
Combining with medicines
Researchers are testing TACE and SIRT together with immunotherapy and targeted drugs. The idea is that the local treatment kills tumour cells and releases signals that help the immune system, while the medicines control cancer elsewhere. Several trials have reported encouraging results, and these combinations may become more common.
What results mean for you
For most people with intermediate liver cancer, TACE and SIRT control the cancer rather than cure it. They can keep tumours in check for many months, and sometimes for years. In selected people, they can shrink tumours enough to allow surgery, ablation or a liver transplant.
8. Recovery and aftercare
Recovery timeline
| Period | What to expect |
|---|---|
| First 1-3 days | Pain, fever and nausea, especially after TACE |
| Week 1 | Tiredness and poor appetite gradually improve |
| Weeks 1-2 | Return to normal light activities |
| 4-12 weeks | Scan to check response |
| Every few months | Repeat TACE or other treatment as needed |
Practical tips
- Rest for the first few days and gradually increase activity
- Take pain relief and anti-sickness medicine as prescribed
- Check the puncture site for swelling or bleeding
- Seek help for high fever, worsening pain, yellow skin or confusion
- Avoid alcohol, which can strain the liver
Living with liver cancer
Liver cancer often develops alongside long-term liver disease. Looking after the liver through treating hepatitis, avoiding alcohol, managing weight and controlling diabetes helps both the cancer treatment and overall health. Specialist liver nurses and patient groups can offer support.
Eating well
Poor appetite and early fullness are common with liver cancer. Small, frequent meals with enough protein help maintain strength. A dietitian can advise on salt intake if fluid builds up in the abdomen.
9. Alternatives
| Alternative | When it is considered |
|---|---|
| Surgical resection | Tumours that can be removed with enough healthy liver left |
| Liver transplant | Selected people with HCC and cirrhosis |
| Thermal ablation | Small tumours |
| Stereotactic or proton radiotherapy | Selected tumours; see proton beam therapy |
| Immunotherapy | Advanced HCC; see immune checkpoint inhibitors |
| Targeted tablets | Sorafenib, lenvatinib and others |
| PRRT | Neuroendocrine liver metastases |
| Supportive care | When liver function is poor |
Ask your team which option is most likely to help you, and what the next step would be if the first treatment does not work.
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is it an operation? | No; it is done through a small puncture in an artery |
| Will I be asleep? | Usually sedated but awake |
| Will I lose my hair? | Hair loss is uncommon because little chemotherapy reaches the rest of the body |
| How many treatments will I need? | TACE is often repeated; SIRT is usually one or two sessions |
| Will I be radioactive after SIRT? | Only slightly, mainly inside the liver; your team will give simple advice |
| Can it help me get a transplant? | Sometimes, by shrinking tumours to within transplant criteria |
| Which is better, TACE or SIRT? | It depends on the tumour, liver function and local expertise |
11. Questions to ask your care team
- Would TACE or SIRT suit me better, and why?
- How is my liver function, and is treatment safe?
- How many sessions might I need?
- What side effects should I expect?
- Could this help me qualify for surgery or transplant?
- When will I have a scan to check the result?
- What are the alternatives if it does not work?
Resources
- Llovet, J.M. et al. (2002) ‘Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial’, The Lancet, 359(9319), pp. 1734-1739.
- Lo, C.M. et al. (2002) ‘Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma’, Hepatology, 35(5), pp. 1164-1171.
- Vilgrain, V. et al. (2017) ‘Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial’, The Lancet Oncology, 18(12), pp. 1624-1636.
- National Cancer Institute (2026) Primary Liver Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/liver/hp/adult-liver-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.